Calvo D B, Patt Y Z, Wallace S, Chuang V P, Benjamin R S, Pritchard J D, Hersh E M, Bodey G P, Mavligit G M
Cancer. 1980 Mar 15;45(6):1278-83. doi: 10.1002/1097-0142(19800315)45:6<1278::aid-cncr2820450603>3.0.co;2-i.
Forty-nine patients with regionally confined recurrent malignancy were treated with intra-arterial cis-diamminedichloro platinum II in a Phase I-II trial. A safe starting dose of 120 mg/m2 was established. An overall response rate of 45% was noted with significant responses observed among patients with melanoma, sarcoma, breast carcinoma, and neuroblastoma. Side effects included transient renal and bone marrow toxicity as well as neurotoxicity and ototoxicity (6%), the latter usually with residual damage. The rational basis and advantages of treatment with intra-arterial cis-platinum are discussed.
在一项I-II期试验中，对49例局部复发的恶性肿瘤患者进行了动脉内顺二氨二氯铂II治疗。确定了120mg/m²的安全起始剂量。总体缓解率为45%，在黑色素瘤、肉瘤、乳腺癌和神经母细胞瘤患者中观察到显著缓解。副作用包括短暂的肾毒性和骨髓毒性以及神经毒性和耳毒性（6%），后者通常会造成残留损害。讨论了动脉内顺铂治疗的理论基础和优势。
